相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies
Lukas Kevlicius et al.
BONE MARROW TRANSPLANTATION (2022)
Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia
Lu Bai et al.
BMC CANCER (2022)
Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy
Montserrat Estruch et al.
LEUKEMIA (2021)
The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles
Elise Aasebo et al.
CANCERS (2020)
Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
Salihanur Darici et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Apoptosis targeted therapies in acute myeloid leukemia: an update
Somedeb Ball et al.
EXPERT REVIEW OF HEMATOLOGY (2020)
Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
Yunxiong Wei et al.
FRONTIERS IN ONCOLOGY (2020)
A compound combination screening approach with potential to identify new treatment options for paediatric acute myeloid leukaemia
Katrina M. Lappin et al.
SCIENTIFIC REPORTS (2020)
Venetoclax-based therapies for acute myeloid leukemia
Veronica A. Guerra et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
Molecular Approaches to Treating Pediatric Leukemias
Michaela Kuhlen et al.
FRONTIERS IN PEDIATRICS (2019)
Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
Raoul Tibes et al.
FRONTIERS IN ONCOLOGY (2019)
Cell cycle regulation and hematologic malignancies
Yun Dai et al.
BLOOD SCIENCE (2019)
The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions
Hamid Bolouri et al.
NATURE MEDICINE (2018)
Post-translational modifications of VDAC1 and VDAC2 cysteines from rat liver mitochondria
Rosaria Saletti et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS (2018)
Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2
Meidan Ying et al.
BLOOD (2018)
Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
Bibi Kulsoom et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Combination therapy in combating cancer
Reza Bayat Mokhtari et al.
ONCOTARGET (2017)
Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia
Elena Arriazu et al.
FRONTIERS IN ONCOLOGY (2016)
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy
Harry P. Erba
LEUKEMIA RESEARCH (2015)
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
G. S. Choudhary et al.
CELL DEATH & DISEASE (2015)
Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
X. Niu et al.
LEUKEMIA (2014)
Essential Thrombocytosis: Redefinition in the Genomic Era
Donna M. Williams et al.
BLOOD (2014)
AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo
Erica Hansen et al.
BLOOD (2014)
CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies
Shuang Chen et al.
CANCER RESEARCH (2012)
Mcl-1 Phosphorylation Defines ABT-737 Resistance That Can Be Overcome by Increased NOXA Expression in Leukemic B cells
Suparna Mazumder et al.
CANCER RESEARCH (2012)
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
Sophie Park et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Mono- or Double-Site Phosphorylation Distinctly Regulates the Proapoptotic Function of Bax
Qinhong Wang et al.
PLOS ONE (2010)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells
V. Papa et al.
LEUKEMIA (2008)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Mark F. van Delft et al.
CANCER CELL (2006)
Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors Bax and Bak
Arata Tomiyama et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak
N Majewski et al.
MOLECULAR CELL (2004)
Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils
SJ Gardai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2
M Shitashige et al.
JOURNAL OF BIOCHEMISTRY (2001)
Phosphorylation of Bcl2 and regulation of apoptosis
PP Ruvolo et al.
LEUKEMIA (2001)
分享论文
